Ariana Pelosci

Articles

BAY 2927088 Displays Durable Responses in HER2-Mutated NSCLC

September 9th 2024

BAY 2927088 demonstrated durable response rates for patients with pretreated HER2-mutant non–small cell lung cancer.

Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma

September 6th 2024

The uptake of subcutaneous rituximab has lagged behind the use of the intravenous version in non-Hodgkin lymphoma.

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

September 6th 2024

Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

No OS Difference Observed After Various Immunotherapy/TKI Regimens in Advanced RCC

July 12th 2024

Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.

Multimodal AI Approach May Help Identify Key Elements to Predict Outcomes in RCC

July 11th 2024

Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.

Nivolumab/Ipilimumab/Radiation Combo Produces Responses in Locally Advanced Rectal Cancer

July 1st 2024

The EA2201 trial evaluated nivolumab, ipilimumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma

June 18th 2024

Ide-cel induced durable responses and had a favorable risk-benefit profile in patients with functionally high-risk multiple myeloma.

Liso-Cel Associated With Improved Benefit in Earlier Lines of Therapy in R/R Mantle Cell Lymphoma

June 14th 2024

Clinically meaningful activity was found across all subgroups in a posthoc subgroup analysis of patients with MCL treated with liso-cel.

Daratumumab Retreatment Leads to Responses in Relapsed/Refractory Myeloma

June 5th 2024

Retreatment with daratumumab-based regimens led to a similar ORR vs initial daratumumab treatment in relapsed/refractory myeloma.

DFS, OS Benefit Maintained With Adjuvant Atezolizumab vs BSC in Stage II/IIIA NSCLC

June 3rd 2024

Long-term DFS and OS outcomes with adjuvant atezolizumab in stage II to IIIA NSCLC were consistent with prior data from the IMpower010 trial.

CRS, ICANS Incidence Reduced to Zero Following Tocilizumab, Teclistamab Administration in R/R Multiple Myeloma

June 3rd 2024

Tocilizumab plus teclistamab step-up dosing showed efficacy and a mainly mild safety profile in patients with relapsed/refractory multiple myeloma.

Nivolumab/Ipilimumab Bests Nivolumab in Ovarian and Extra-Renal Clear Cell Carcinomas

June 2nd 2024

The combination of nivolumab and ipilimumab improved responses as well as survival outcomes in patients with ovarian or gynecologic clear cell carcinomas.

Lymphadenectomy Fails to Boost Survival in Advanced Ovarian Cancer

June 2nd 2024

The addition of lymphadenectomy to cytoreductive surgery did not improve progression-free or overall survival in advanced ovarian cancer.

18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer

May 3rd 2024

18F-PSMA-1007 PET/CT generated superior locoregional staging results vs multiparametric MRI in patients with prostate cancer.

Exosome-Based Assay Shows Diagnostic Sensitivity, Specificity in Pancreatic Cancer

April 8th 2024

A microRNA assay combined with CA19-9 displayed diagnostic accuracy in the early detection of pancreatic cancer.

Post-Surgery Atezolizumab Fails to Provide Benefit in Combination With Chemotherapy for TNBC

March 23rd 2024

Adjuvant atezolizumab did not provide a clinical benefit when added to chemotherapy in patients with triple-negative breast cancer.

AI Models May Serve As Additional Genetic Counseling Resource in Gynecologic Oncology

March 18th 2024

ChatGPT may provide comprehensive and correct answers to genetic counseling questions for patients with gynecologic cancers.

Pembrolizumab Plus Chemo Generates Favorable OS Trend in Endometrial Cancer

March 16th 2024

The addition of pembrolizumab to chemotherapy led to a favorable overall survival benefit vs chemotherapy plus placebo in endometrial cancer.

Ruxolitinib Cream Is Tolerable and Effective in Cutaneous GVHD

February 23rd 2024

A cream formulation of ruxolitinib was deemed safe and effective compared with placebo in patients with cutaneous graft-versus-host disease.

DKN-01 Plus Bevacizumab and Chemotherapy Shows Tolerability, Activity in MSS CRC

January 20th 2024

DKN-01/bevacizumab/chemotherapy had a tolerable safety profile and showcased clinical activity in patients with microsatellite stable colorectal cancer.